BiotechTube

Letrozole

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Postmenopausal Women With Advanced Breast Cancer

Conditions

Postmenopausal Women With Advanced Breast Cancer

Trial Timeline

Dec 1, 1999 → —

NCT ID
NCT00247663

About Letrozole

Letrozole is a phase 2 stage product being developed by Chugai Pharmaceutical for Postmenopausal Women With Advanced Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00247663. Target conditions include Postmenopausal Women With Advanced Breast Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (3)

NCT IDPhaseStatus
NCT00237198Phase 2Completed
NCT00237211Phase 2Completed
NCT00247663Phase 2Completed

Competing Products

20 competing products in Postmenopausal Women With Advanced Breast Cancer

See all competitors
ProductCompanyStageHype Score
ENZ215 + ProliaAlkem LaboratoriesPhase 3
77
teriparatide + teriparatide + Placebo + Calcium Supplement + Vitamin D SupplementEli LillyPhase 3
77
teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneousEli LillyPhase 3
77
CT-P41 + US-licensed ProliaCelltrionPhase 3
77
Eldecalcitol soft capsulesChugai PharmaceuticalPre-clinical
23
LetrozoleChugai PharmaceuticalPhase 2
52
LetrozoleChugai PharmaceuticalPhase 2
52
menatetranone + alfacalcidolEisaiPhase 3
77
teriparatide + raloxifene + placeboEli LillyPhase 3
77
Teriparatide + Strontium ranelateEli LillyApproved
85
teriparatideEli LillyApproved
85
LY333334 + PlaceboEli LillyPhase 1
33
Teriparatide + RaloxifeneEli LillyApproved
85
teriparatide + aldrenodate + raloxifeneEli LillyApproved
85
LAE102 SC + Placebo SC + LAE102 IV + Placebo IVEli LillyPhase 1
33
BlosozumabEli LillyPhase 1
33
BlosozumabEli LillyPhase 1
33
Arzoxifene + RaloxifeneEli LillyPhase 3
77
teriparatide + raloxifene HCl + placeboEli LillyApproved
85
Raloxifene HCL + Raloxifene HCL + PlaceboEli LillyPhase 3
77

Other Products from Chugai Pharmaceutical

Satralizumab 120 mgApproved
85
Pegasys® + Pegasys®Approved
85
ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placeboPhase 3
77
R744 + Epoetin betaPhase 3
77
EmicizumabPhase 3
77